MedTrace Logo

Pharmacokinetics of Piperacillin and Meropenem in ICU Patients

NCT05134298 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-11-24

No results posted yet for this study

Summary

The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.

Conditions

  • Antibiotic Pharmacokinetics

Interventions

DRUG

Piperacillin/tazobactam, Meropenem

This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134298 on ClinicalTrials.gov